Kerstin Lüedtke-Heckenkamp

Fractalkine Is an Epithelial and Endothelial Cell-Derived Chemoattractant for Intraepithelial Lymphocytes in the Small Intestinal Mucosa

Andreas Muehlhoefer, Lawrence J. Saubermann, Xuibin Gu et al. · The Journal of Immunology · 2000 · 251 citations · Full text

Life Sciences, Cell Biology, Immunology +16

Cetuximab, docetaxel, and cisplatin versus platinum, fluorouracil, and cetuximab as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (GORTEC 2014-01 TPExtreme): a multicentre, open-label, randomised, phase 2 trial

J. Guigay, Anne Aupérin, Jérôme Fayette et al. · The Lancet Oncology · 2021 · 232 citations

Medicine, Oncology, Chemotherapy +14

<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer

Isabel Grote, Stephan Bartels, Leonie Donata Kandt et al. · Cancer Medicine · 2021 · 41 citations · Full text

Medicine, Endocrinology, Oncology +17

Efficacy of Endocrine Therapy Plus Trastuzumab and Pertuzumab vs De-escalated Chemotherapy in Patients with Hormone Receptor–Positive/<i>ERBB2</i>-Positive Early Breast Cancer

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · JAMA Oncology · 2023 · 36 citations · Full text

Medicine, Oncology, Pharmacology +17

De-escalated chemotherapy versus endocrine therapy plus pertuzumab+ trastuzumab for HR+/HER2+ early breast cancer (BC): First efficacy results from the neoadjuvant WSG-TP-II study.

Oleg Gluz, Ulrike Nitz, Matthias Christgen et al. · Journal of Clinical Oncology · 2020 · 14 citations

Medicine, Oncology, Pharmacology +17